<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22616020</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>5</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses.</ArticleTitle><Pagination><StartPage>e1645</StartPage><MedlinePgn>e1645</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1645</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0001645</ELocationID><Abstract><AbstractText>The major weaknesses of subunit vaccines are their low immunogenicity and poor efficacy. Adjuvants can help to overcome some of these inherent defects with subunit vaccines. Here, we evaluated the efficacy of the newly developed water-in-oil-in-water multiphase emulsion system, termed PELC, in potentiating the protective capacity of dengue-1 envelope protein domain III. Unlike aluminum phosphate, dengue-1 envelope protein domain III formulated with PELC plus CpG oligodeoxynucleotides induced neutralizing antibodies against dengue-1 virus and increased the splenocyte secretion of IFN-&#x3b3; after in vitro re-stimulation. The induced antibodies contained both the IgG1 and IgG2a subclasses. A rapid anamnestic neutralizing antibody response against a live dengue virus challenge was elicited at week 26 after the first immunization. These results demonstrate that PELC plus CpG oligodeoxynucleotides broaden the dengue-1 envelope protein domain III-specific immune responses. PELC plus CpG oligodeoxynucleotides is a promising adjuvant for recombinant protein based vaccination against dengue virus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Chen-Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ming-Hsi</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Chun-Hsiang</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Yu</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hsueh-Hung</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jy-Ping</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi-Shiuan</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Ching-Yun</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shih-Jen</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Chih-Hsiang</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsin-Wei</ForeName><Initials>HW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C408982">CPG-oligonucleotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009821">Oils</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009838">Oligodeoxyribonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009821" MajorTopicYN="N">Oils</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009838" MajorTopicYN="N">Oligodeoxyribonucleotides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>MHH, PC, CHL, SJL, and HWC are named on patents relating to the preparation and use of multi-phase emulsions based on amphiphilic block copolymers. This does not alter the authors' adherence to all the PLoS Neglected Tropical Diseases policies on sharing data and materials. All other authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22616020</ArticleId><ArticleId IdType="pmc">PMC3352863</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0001645</ArticleId><ArticleId IdType="pii">PNTD-D-11-01207</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8:S7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333201</ArticleId><ArticleId IdType="pubmed">21079655</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Dengue. Lancet. 2007;370:1644&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17993365</ArticleId></ArticleIdList></Reference><Reference><Citation>Coller BA, Clements DE. Dengue vaccines: progress and challenges. Curr Opin Immunol. 2011;23:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">21514129</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine. 2011;29:7276&#x2013;7284.</Citation><ArticleIdList><ArticleId IdType="pubmed">21781998</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5:518&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17558424</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med. 1997;3:866&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">9256277</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung J-J, Hsieh M-T, Young M-J, Kao C-L, King C-C, et al. An External Loop Region of Domain III of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells. J Virol. 2004;78:378&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC303388</ArticleId><ArticleId IdType="pubmed">14671119</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Roehrig JT. Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells. J Virol. 2001;75:7769&#x2013;7773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC115016</ArticleId><ArticleId IdType="pubmed">11462053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiramatsu K, Tadano M, Men R, Lai C-J. Mutational Analysis of a Neutralization Epitope on the Dengue Type 2 Virus (DEN2) Envelope Protein: Monoclonal Antibody Resistant DEN2/DEN4 Chimeras Exhibit Reduced Mouse Neurovirulence. Virology. 1996;224:437&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">8874504</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT, Bolin RA, Kelly RG. Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica. Virology. 1998;246:317&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657950</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT, Risi PA, Brubaker JR, Hunt AR, Beaty BJ, et al. T-Helper Cell Epitopes on the E-Glycoprotein of Dengue 2 Jamaica Virus. Virology. 1994;198:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">7505071</ArticleId></ArticleIdList></Reference><Reference><Citation>Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol. 2001;82:1885&#x2013;1892.</Citation><ArticleIdList><ArticleId IdType="pubmed">11457994</ArticleId></ArticleIdList></Reference><Reference><Citation>Trirawatanapong T, Chandran B, Putnak R, Padmanabhan R. Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene. 1992;116:139&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125935</ArticleId><ArticleId IdType="pubmed">1634111</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines. 2010;9:137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">20109025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res. 2008;80:194&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">18602424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo L, Pavon A, Hermida L, Gil L, Valdes I, et al. The two component adjuvant IC31(R) potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine. 2011;29:4256&#x2013;4263.</Citation><ArticleIdList><ArticleId IdType="pubmed">21447316</ArticleId></ArticleIdList></Reference><Reference><Citation>Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, et al. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine. 2010;28:8085&#x2013;8094.</Citation><ArticleIdList><ArticleId IdType="pubmed">20959154</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Liu SJ, Liu HH, Kwok Y, Lin CL, et al. A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine. 2009;27:1400&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pubmed">19150476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Liu SJ, Tsai JP, Li YS, Chen MY, et al. A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One. 2011;6:e23319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149651</ArticleId><ArticleId IdType="pubmed">21826249</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng CH, Chen HW, Chang LS, Liu HH, Liu HY, et al. A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol Immunol. 2010;47:2015&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">20478617</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009;11:288&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology. 2009;394:249&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">19783271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulueta A, Martin J, Hermida L, Alvarez M, Valdes I, et al. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res. 2006;121:65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">16781791</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang MH, Chou AH, Lien SP, Chen HW, Huang CY, et al. Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)-block-poly(lactide-co-epsilon-caprolactone). J Biomed Mater Res B Appl Biomater. 2009;90:832&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">19280632</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang MH, Huang CY, Lien SP, Siao SY, Chou AH, et al. Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm Res. 2009;26:1856&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">19415466</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang MH, Huang CY, Lin SC, Chen JH, Ku CC, et al. Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes Infect. 2009;11:654&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">19344782</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang MH, Lin SC, Hsiao CH, Chao HJ, Yang HR, et al. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One. 2010;5:e12279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924384</ArticleId><ArticleId IdType="pubmed">20808862</ArticleId></ArticleIdList></Reference><Reference><Citation>Stemmer WPC, Crameri A, Ha KD, Brennan TM, Heyneker HL. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene. 1995;164:49&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">7590320</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Rodriguez R, Hermida L, Alvarez M, Lazo L, et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg. 2003;69:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">13677367</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine. 2005;23:4442&#x2013;4452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16005749</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol. 2006;80:9577&#x2013;9585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1617260</ArticleId><ArticleId IdType="pubmed">16973561</ArticleId></ArticleIdList></Reference><Reference><Citation>Velzing J, Groen J, Drouet MT, van Amerongen G, Copra C, et al. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine. 1999;17:1312&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremont DH, et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe. 2007;2:417&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2194657</ArticleId><ArticleId IdType="pubmed">18078693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med. 2008;205:869&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2292225</ArticleId><ArticleId IdType="pubmed">18362170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kool M, Willart MA, van Nimwegen M, Bergen I, Pouliot P, et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity. 2011;34:527&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">21474346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity. 2011;34:514&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">21497116</ArticleId></ArticleIdList></Reference><Reference><Citation>Serre K, Benezech C, Desanti G, Bobat S, Toellner KM, et al. Helios is associated with CD4 T cells differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 expression. PLoS One. 2011;6:e20731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108993</ArticleId><ArticleId IdType="pubmed">21677778</ArticleId></ArticleIdList></Reference><Reference><Citation>Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, et al. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol. 2004;78:2701&#x2013;2710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC353772</ArticleId><ArticleId IdType="pubmed">14990690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol. 2009;182:4865&#x2013;4873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674070</ArticleId><ArticleId IdType="pubmed">19342665</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>